October 2 - 3, 2018
5th NCI Pancreatic Cancer Symposium

Building 35
Room 610/620/630/640

Organized by: NCI-Pancreatic Cancer Interest Group and The University Medical Center, Göttingen, Germany

About the Symposium

Pancreatic cancer remains one of the most lethal malignancies and is the 4th leading cause of death due to cancer in the United States with a median survival of less than 6 months. The purpose of the 5th NCI Pancreatic Cancer Symposium is to provide an opportunity to bring together the leaders and young investigators including basic researchers and clinical scientists in the field from NCI/NIH and extramural community to exchange information and understand the latest advances in tumor biology, epidemiology, early detection and treatment of pancreatic cancer. The meeting will provide an exciting forum to foster collaborations and to address future challenges in advancing our commitment of improving disease outcome in patients with this recalcitrant cancer.


  •      David Tuveson, M.D., Ph.D., Cold Spring Harbor Laboratory, NY
  •      Ben Stanger, University of Pennsylvania School of Medicine, Philadelphia, PA
  •      Diane Simeone, M.D., NYU Langone Medical Ctr. NY
  •      Teresa Brentnall, M.D., Univ. Washington School of Medicine, WA
  •      Jason Fleming, M.D., Moffitt Cancer Center, Tampa, FL
  •      Anne Marie Lennon M.D., Ph.D., Johns Hopkins School of Medicine, Baltimore, MD
  •      Darren Carpizo, M.D., Ph.D., Rutgers Robert Wood-Johnson Univ. Medical School, NJ
  •      Volker Ellenrieder, M.D., University Medical Center, Gottingen, Germany
  •      Thilo Hackert, M.D., Heidelberg University Hospital, Heidelberg, Germany

(Please see agenda for a complete list of speakers)


  •      S. Perwez Hussain
  •      Christine Alewine
  •      Laufey Amundadottir
  •      Raffit Hassan
  •      Thomas Ried
  •      Michael Ghadimi
  •      Jochen Gaedcke
  •      Volker Ellenrieder
  •      Philipp Ströbel

Main Topics

  • Tumor Biology and Disease Progression
  • Novel Therapeutic Targets
  • Early Detection
  • Inflammatory and Immune Signaling
  • Metabolic Reprogramming
  • Genetics and Epigenetics
  • Treatment and Clinical Advances


Registration is currently closed.